Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Item No. 21422

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
(–)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1 In vivo, (–)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2 (–)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (–)- and (±)-bupivacaine (Item No. 16618).3 Formulations containing (–)-ropivacaine have been used as local anesthetics during surgery and childbirth.
WARNING This product is not for human or veterinary use.
1. Ropivacaine: A pharmacological review. Exp. Rev. Neurother. 4(5), 781-791 (2004).
2. Levobupivacaine versus ropivacaine for sciatic nerve block in the rat. Reg. Anesth. Pain Med. 28(4), 294-303 (2003).
3. Myocardial contractility impairment with racemic bupivacaine, non-